Observational non-interventional registry study of trastuzumab biosimilar in patients with Early Breast Cancer
Not Applicable
- Conditions
- Health Condition 1: -
- Registration Number
- CTRI/2018/11/016306
- Lead Sponsor
- Biocon Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other (Terminated)
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patient aged � 18 years
Patients who are willing to provide written and signed informed consent for collecting health data into the registry
Patients with EBC who are eligible to receive treatment with Trastuzumab as per the approved prescribing information and clinical judgment of the treating oncologist
Exclusion Criteria
1.Have a history of hypersensitivity to Trastuzumab or other components of the product
2.Patient with any contraindication as mentioned in approved prescribing information of Trastuzumab biosimilar
3.Any other reason (concurrent disease or condition) in the opinion of the oncologist that would make the patient unsuitable for participation in the registry
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method